News
Veliparib improves PFS in high-grade serous epithelial ovarian cancer
BARCELONA – Adding veliparib to frontline CT and maintenance significantly extended PFS in women with high-grade...
News
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
News
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...
News
PRIMA study: Niraparib maintenance improves PFS in advanced OC
BARCELONA – Niraparib improves PFS when given after first-line chemotherapy for advanced ovarian cancer, according...
News
mIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinoma
BARCELONA - The first-in-class oral inhibitor of mIDH1, significantly improved PFS for advanced cholangiocarcinoma in the global, randomized,...
News
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
BARCELONA – MONARCH 2 trial data show that adding the CDK4/6 inhibitor abemaciclib to fulvestrant significantly improves overall survival in HR+,...
News
PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer
BARCELONA – Benefit was particularly pronounced in patients with a tumor BRCA mutation and those with homologous recombination deficiency (HRD)–...
News
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
News
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroups
BARCELONA – Combination nivolumab and ipilimumab showed good safety and encouraging clinical activity in patients with advanced NSCLC, despite...
News
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
News
Cancer drug prices higher in U.S. than Europe; don’t correlate with clinical benefit
BARCELONA – Cancer drug prices are significantly higher in the United states than in Europe, and they don’t correlate with clinical benefit in...
News
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
News
OS benefit with pembrolizumab endures long-term in advanced NSCLC
BARCELONA – First-line pembrolizumab provides a durable long-term OS benefit, compared with that of chemotherapy, in patients with advanced...
News
IMpower131: Improvement in OS for stage IV NSCLC+high-PD-L1 expression
BARCELONA – Patients in the IMpower131 trial with high PD-L1 expression experienced a clinically meaningful improvement in OS with atezolizumab +...